Treatment trials in progressive MS - Current challenges and future directions

Nature Reviews Neurology

Volumn 9, Issue 9, 2013, Pages 496-503

  Koch, Marcus W ^a   Cutter, Gary ^b   Stys, Peter K ^b   Yong, V Wee ^b   Metz, Luanne M ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b Ryals Public Health Building ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; LAMOTRIGINE; LAQUINIMOD; MICRORNA; MICRORNA 155; MICRORNA 338; MICRORNA 491; MINOCYCLINE; NATALIZUMAB; NEUROFILAMENT PROTEIN; OCRELIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

AXONAL INJURY; CLINICAL TRIAL (TOPIC); COGNITION; DEMYELINATION; DISABILITY; DISEASE COURSE; ENCEPHALITIS; EXPANDED DISABILITY STATUS SCALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; REVIEW; VISION;

CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT OUTCOME;

EID: 84883742744     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.148     Document Type: Review

References (87)

1. Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). (Pubitemid 34304266)
2. Miller, D. H. & Leary, S. M. Primary-progressive multiple sclerosis. Lancet Neurol. 6, 903-912 (2007). (Pubitemid 47405002)
3. Rovaris, M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5, 343-354 (2006).
4. [No authors listed]. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498-1504 (1998).
5. [No authors listed]. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon β-1b in secondary progressive MS. Lancet 352, 1491-1497 (1998).
6. Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
7. Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
8. Killestein, J., Rudick, R. A. & Polman, C. H. Oral treatment for multiple sclerosis. Lancet Neurol. 10, 1026-1034 (2011).
9. Meuth, S. G., Göbel, K. & Wiendl, H. Immune therapy of multiple sclerosis-future strategies. Curr. Pharm. Des. 18, 4489-4497 (2012).
10. La Mantia, L., Munari, L. M. & Lovati, R. Glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews, Issue 12. Art No.: CD004678. http://dx.doi.org/10.1002/14651858.CD004678.pub2.
11. La Mantia, L. et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD005181. http://dx.doi.org/10.1002/14651858.CD005181.pub3.
12. Bjartmar, C., Wujek, J. R. & Trapp, B. D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165-171 (2003). (Pubitemid 36143722)
13. Bjartmar, C. & Trapp, B. D. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox. Res. 5, 157-164 (2003).
14. Antel, J., Antel, S., Caramanos, Z., Arnold, D. L. & Kuhlmann, T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 123, 627-638 (2012).
15. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005). (Pubitemid 41552953)
16. Lassmann, H., Van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8, 647-656 (2012).
17. Calabrese, M. et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135, 2952-2961 (2012).
18. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452 (1983). (Pubitemid 14237132)
19. Leray, E. et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 133, 1900-1913 (2010).
20. Scalfari, A. et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133, 1914-1929 (2010).
21. Confavreux, C., Vukusic, S. & Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770-782 (2003). (Pubitemid 36372978)
22. Prineas, J. W. et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646-657 (2001). (Pubitemid 33021923)
23. Jackson, S. J., Giovannoni, G. & Baker, D. Fingolimod modulates microglial activation to augment markers of remyelination. J. Neuroinflammation 8, 76 (2011).
24. Brück, W. et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411-424 (2012).
25. Wilms, H. et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 7, 30 (2010).
26. Yong, V. W. et al. The promise of minocycline in neurology. Lancet Neurol. 3, 744-751 (2004). (Pubitemid 39535260)
27. Nikolakopoulou, A. M., Dutta, R., Chen, Z., Miller, R. H. & Trapp, B. D. Activated microglia enhance neurogenesis via trypsinogen secretion. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/pnas.1218856110.
28. Gonsette, R. E. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci. 274, 48-53 (2008).
29. Salter, M. G. & Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438, 1167-1171 (2005). (Pubitemid 41831687)
30. Micu, I. et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439, 988-992 (2006). (Pubitemid 43292418)
31. Ouardouz, M. et al. Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann. Neurol. 65, 160-166 (2009).
32. Irvine, K. A. & Blakemore, W. F. Remyelination protects axons from demyelination-associated axon degeneration. Brain 131, 1464-1477 (2008). (Pubitemid 351806463)
33. Rudick, R. A., Mi, S. & Sandrock, A. W. Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert. Opin. Biol. Ther. 8, 1561-1570 (2008).
34. Keough, M. B. & Yong, V. W. Remyelination therapy for multiple sclerosis. Neurotherapeutics 10, 44-54 (2013).
35. Madeddu, R. et al. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol. Sci. 34, 181-186 (2013).
36. Koch, M. W., Metz, L. M. & Kovalchuk, O. Epigenetic changes in patients with multiple sclerosis. Nat. Rev. Neurol. 9, 35-43 (2013).
37. Koch, M. W., Metz, L. M. & Kovalchuk, O. Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. Trends Mol. Med. 19, 23-30 (2013).
38. Noorbakhsh, F. et al. Impaired neurosteroid synthesis in multiple sclerosis. Brain 134, 2703-2721 (2011).
39. Rajasekharan, S. & Bar-Or, A. From bench to MS bedside: challenges translating biomarker discovery to clinical practice. J. Neuroimmunol. 248, 66-72 (2012).
40. Wolinsky, J. S. et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61, 14-24 (2007). (Pubitemid 46214240)
41. Hommes, O. R. et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149-1156 (2004). (Pubitemid 39296602)
42. Panitch, H., Miller, A., Paty, D. & Weinshenker, B. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63, 1788-1795 (2004). (Pubitemid 39532370)
43. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56, 1496-1504 (2001).
44. Bosma, L. V. et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult. Scler. 15, 715-720 (2009).
45. Ontaneda, D., Larocca, N., Coetzee, T. & Rudick, R. Revisiting the Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. Mult. Scler. 18, 1074-1080 (2012).
46. Amato, M. P., Fratiglioni, L., Groppi, C., Siracusa, G. & Amaducci, L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch. Neurol. 45, 746-748 (1988).
47. Francis, D. A., Bain, P., Swan, A. V. & Hughes, R. A. An assessment of disability rating scales used in multiple sclerosis. Arch. Neurol. 48, 299-301 (1991).
48. Noseworthy, J. H., Vandervoort, M. K., Wong, C. J. & Ebers, G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40, 971-975 (1990). (Pubitemid 20201827)
49. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114, 1057-1067 (1991).
50. Cohen, J. A. et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 59, 679-687 (2002).
51. Cutter, G. R. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871-882 (1999). (Pubitemid 29219261)
52. Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 9, 681-688 (2010).
53. Hoogervorst, E. L. et al. Comparisons of patient self-report, neurologic examination, and functional impairment in MS. Neurology 56, 934-937 (2001). (Pubitemid 32290811)
54. Hoogervorst, E. L., Kalkers, N. F., Cutter, G. R., Uitdehaag, B. M. & Polman, C. H. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult. Scler. 10, 55-60 (2004). (Pubitemid 38100527)
55. Miller, D. M., Rudick, R. A., Cutter, G., Baier, M. & Fischer, J. S. Clinical significance of the Multiple Sclerosis Functional Composite: relationship to patient-reported quality of life. Arch. Neurol. 57, 1319-1324 (2000).
56. Solari, A., Radice, D., Manneschi, L., Motti, L. & Montanari, E. The Multiple Sclerosis Functional Composite: different practice effects in the three test components. J. Neurol. Sci. 228, 71-74 (2005). (Pubitemid 39656497)
57. Schwid, S. R., Goodman, A. D., McDermott, M. P., Bever, C. F. & Cook, S. D. Quantitative functional measures in MS: what is a reliable change? Neurology 58, 1294-1296 (2002). (Pubitemid 34411881)
58. Bosma, L. V. et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult. Scler. 16, 862-867 (2010).
59. Kragt, J. J., van der Linden, F. A., Nielsen, J. M., Uitdehaag, B. M. & Polman, C. H. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult. Scler. 12, 594-598 (2006). (Pubitemid 46940633)
60. Polman, C. H. & Rudick, R. A. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 74 (Suppl. 3), S8-S15 (2010).
61. Tombaugh, T. N. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch. Clin. Neuropsychol. 21, 53-76 (2006). (Pubitemid 41802927)
62. Scherer, P. Cognitive screening in multiple sclerosis. J. Neurol. 254 (Suppl. 2), II26-II29 (2007).
63. Parmenter, B. A., Weinstock-Guttman, B., Garg, N., Munschauer, F. & Benedict, R. H. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult. Scler. 13, 52-57 (2007). (Pubitemid 46152761)
64. Morrow, S. A. et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin. Neuropsychol. 24, 1131-1145 (2010).
65. Balcer, L. J. & Frohman, E. M. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology 74 (Suppl. 3), S16-S23 (2010).
66. Balcer, L. J. et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult. Scler. 6, 163-171 (2000). (Pubitemid 30392113)
67. Mowry, E. M. et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J. Neurol. Neurosurg. Psychiatry 80, 767-772 (2009).
68. Frohman, E. M. et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62, 1345-1356 (2005). (Pubitemid 41352050)
69. Daumer, M., Neuhaus, A., Morrissey, S., Hintzen, R. & Ebers, G. C. MRI as an outcome in multiple sclerosis clinical trials. Neurology 72, 705-711 (2009).
70. Geurts, J. J., Calabrese, M., Fisher, E. & Rudick, R. A. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 11, 1082-1092 (2012).
71. Altmann, D. R. et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 72, 595-601 (2009).
72. Cohen, J. A., Reingold, S. C., Polman, C. H. & Wolinsky, J. S. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 11, 467-476 (2012).
73. Havrdova, E. et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 8, 254-260 (2009).
74. Giovannoni, G. et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 10, 329-337 (2011).
75. Cottrell, D. A. et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122, 625-639 (1999). (Pubitemid 29158771)
76. Confavreux, C., Vukusic, S., Moreau, T. & Adeleine, P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430-1438 (2000).
77. Koch, M., Kingwell, E., Rieckmann, P. & Tremlett, H. The natural history of primary progressive multiple sclerosis. Neurology 73, 1996-2002 (2009).
78. Tremlett, H., Paty, D. & Devonshire, V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66, 172-177 (2006). (Pubitemid 43970148)
79. US National Institutes of Health. FTY720 in patients with primary progressive multiple sclerosis. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00731692.
80. Mostert, J. P., Koch, M. W., Heerings, M., Heersema, D. J. & De Keyser, J. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci. Ther. 14, 153-164 (2008). (Pubitemid 351713316)
81. Sicotte, N. L. et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421-428 (2002).
82. Garay, L. et al. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res. 1283, 177-185 (2009).
83. Walker, J. E. & Margolin, S. B. Pirfenidone for chronic progressive multiple sclerosis. Mult. Scler. 7, 305-312 (2001). (Pubitemid 33028867)
84. Walker, J. E., Giri, S. N. & Margolin, S. B. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult. Scler. 11, 149-158 (2005). (Pubitemid 40403252)
85. Chataway, J. et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult. Scler. 17, 81-88 (2011).
86. Friede, T. et al. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Stat. Med. 30, 1528-1540 (2011).
87. Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10, 1-10 (1989). (Pubitemid 19099520)